MedMira receives CE Marks on its syphilis/HIV rapid test

MedMira has received CE mark on its syphilis/HIV rapid test, Multiplo TP/HIV, this approval allows company to market and distribute the multiplex rapid test throughout the European Union.

Multiplo enables easy and accurate screening for both Treponema pallidum (TP), the causative agent of syphilis, and HIV simultaneously. Multiplo provides instant results at the point-of-care, helping healthcare providers and their patients know more and begin treatment sooner. Multiplo TP/HIV is especially applicable in helping reduce mother-to-child transmission of syphilis and HIV.

MedMira CEO, Hermes Chan said that their Multiplo TP/HIV tests delivers 100% sensitivity in identifying co-infections and is a key tool for healthcare providers, public health agencies, and aid organizations looking to maximize resources in their prevention and control initiatives. MedMira customers and their patients are benefiting from a higher throughput of patients tested and knowing their status, treatments started, and operational efficiencies achieved with Multiplo.